APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cardiometabolic Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cardiometabolic Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025195 pages

Choose your research edition.

Industry ResearchCardiometabolic Disease Drug Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Cardiometabolic Disease Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Cardiometabolic Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cardiometabolic Disease Drug Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Cardiometabolic Disease Drug Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Cardiometabolic Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cardiometabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cardiometabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cardiometabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cardiometabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cardiometabolic Disease Drug include Qilu Pharmaceutical, Merck, Roche Holding AG, Chengda Pharmaceutical, ZMC, Taj Pharma, Sydler Group, Space Biology and Servier, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cardiometabolic Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cardiometabolic Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cardiometabolic Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cardiometabolic Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Cardiometabolic Disease Drug Segment by Company

Qilu Pharmaceutical

Merck

Roche Holding AG

Chengda Pharmaceutical

ZMC

Taj Pharma

Sydler Group

Space Biology

Servier

Northeast Pharmaceutical

NHU

Lonza Group

Kingdomway

Kaneka

Hengtai Chemical

Biosint

Abbott

Cardiometabolic Disease Drug Segment by Type

Coenzyme Q10

Cyclic Adenosine Monophosphate

Trimetazidine

L-carnitine

Others

Cardiometabolic Disease Drug Segment by Application

Retail Pharmacy

Online Sales

Hospital

Clinic

Others

Cardiometabolic Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiometabolic Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cardiometabolic Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiometabolic Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cardiometabolic Disease Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cardiometabolic Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cardiometabolic Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cardiometabolic Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cardiometabolic Disease Drug Industry Trends Table 2. Cardiometabolic Disease Drug Industry Drivers Table 3. Cardiometabolic Disease Drug Industry Opportunities and Challenges Table 4. Cardiometabolic Disease Drug Industry Restraints Table 5. Global Cardiometabolic Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cardiometabolic Disease Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cardiometabolic Disease Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Cardiometabolic Disease Drug Sales Market Share by Manufacturers Table 9. Global Cardiometabolic Disease Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cardiometabolic Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cardiometabolic Disease Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cardiometabolic Disease Drug Manufacturers, Product Type & Application Table 13. Global Cardiometabolic Disease Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cardiometabolic Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Coenzyme Q10 Table 17. Major Manufacturers of Cyclic Adenosine Monophosphate Table 18. Major Manufacturers of Trimetazidine Table 19. Major Manufacturers of L-carnitine Table 20. Major Manufacturers of Others Table 21. Global Cardiometabolic Disease Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Cardiometabolic Disease Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Cardiometabolic Disease Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Cardiometabolic Disease Drug Sales Market Share by Type (2021-2026) Table 25. Global Cardiometabolic Disease Drug Sales Market Share by Type (2027-2032) Table 26. Global Cardiometabolic Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Cardiometabolic Disease Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Cardiometabolic Disease Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Cardiometabolic Disease Drug Revenue Market Share by Type (2021-2026) Table 30. Global Cardiometabolic Disease Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Retail Pharmacy Table 32. Major Manufacturers of Online Sales Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Clinic Table 35. Major Manufacturers of Others Table 36. Global Cardiometabolic Disease Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Cardiometabolic Disease Drug Sales by Application (2021-2026) & (K Units) Table 38. Global Cardiometabolic Disease Drug Sales by Application (2027-2032) & (K Units) Table 39. Global Cardiometabolic Disease Drug Sales Market Share by Application (2021-2026) Table 40. Global Cardiometabolic Disease Drug Sales Market Share by Application (2027-2032) Table 41. Global Cardiometabolic Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Cardiometabolic Disease Drug Revenue by Application (2021-2026) & (K Units) Table 43. Global Cardiometabolic Disease Drug Revenue by Application (2027-2032) & (K Units) Table 44. Global Cardiometabolic Disease Drug Revenue Market Share by Application (2021-2026) Table 45. Global Cardiometabolic Disease Drug Revenue Market Share by Application (2027-2032) Table 46. Global Cardiometabolic Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Cardiometabolic Disease Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Cardiometabolic Disease Drug Sales Market Share by Region (2021-2026) Table 49. Global Cardiometabolic Disease Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Cardiometabolic Disease Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Cardiometabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 53. North America Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 54. Europe Cardiometabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 56. Europe Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Cardiometabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Cardiometabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Cardiometabolic Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Cardiometabolic Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Cardiometabolic Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Cardiometabolic Disease Drug Revenue Market Share by Region (2021-2026) Table 67. Global Cardiometabolic Disease Drug Revenue Market Share by Region (2027-2032) Table 68. Qilu Pharmaceutical Company Information Table 69. Qilu Pharmaceutical Business Overview Table 70. Qilu Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Qilu Pharmaceutical Cardiometabolic Disease Drug Product Portfolio Table 72. Qilu Pharmaceutical Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck Cardiometabolic Disease Drug Product Portfolio Table 77. Merck Recent Development Table 78. Roche Holding AG Company Information Table 79. Roche Holding AG Business Overview Table 80. Roche Holding AG Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Roche Holding AG Cardiometabolic Disease Drug Product Portfolio Table 82. Roche Holding AG Recent Development Table 83. Chengda Pharmaceutical Company Information Table 84. Chengda Pharmaceutical Business Overview Table 85. Chengda Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Chengda Pharmaceutical Cardiometabolic Disease Drug Product Portfolio Table 87. Chengda Pharmaceutical Recent Development Table 88. ZMC Company Information Table 89. ZMC Business Overview Table 90. ZMC Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. ZMC Cardiometabolic Disease Drug Product Portfolio Table 92. ZMC Recent Development Table 93. Taj Pharma Company Information Table 94. Taj Pharma Business Overview Table 95. Taj Pharma Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Taj Pharma Cardiometabolic Disease Drug Product Portfolio Table 97. Taj Pharma Recent Development Table 98. Sydler Group Company Information Table 99. Sydler Group Business Overview Table 100. Sydler Group Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sydler Group Cardiometabolic Disease Drug Product Portfolio Table 102. Sydler Group Recent Development Table 103. Space Biology Company Information Table 104. Space Biology Business Overview Table 105. Space Biology Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Space Biology Cardiometabolic Disease Drug Product Portfolio Table 107. Space Biology Recent Development Table 108. Servier Company Information Table 109. Servier Business Overview Table 110. Servier Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Servier Cardiometabolic Disease Drug Product Portfolio Table 112. Servier Recent Development Table 113. Northeast Pharmaceutical Company Information Table 114. Northeast Pharmaceutical Business Overview Table 115. Northeast Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Northeast Pharmaceutical Cardiometabolic Disease Drug Product Portfolio Table 117. Northeast Pharmaceutical Recent Development Table 118. NHU Company Information Table 119. NHU Business Overview Table 120. NHU Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. NHU Cardiometabolic Disease Drug Product Portfolio Table 122. NHU Recent Development Table 123. Lonza Group Company Information Table 124. Lonza Group Business Overview Table 125. Lonza Group Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Lonza Group Cardiometabolic Disease Drug Product Portfolio Table 127. Lonza Group Recent Development Table 128. Kingdomway Company Information Table 129. Kingdomway Business Overview Table 130. Kingdomway Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Kingdomway Cardiometabolic Disease Drug Product Portfolio Table 132. Kingdomway Recent Development Table 133. Kaneka Company Information Table 134. Kaneka Business Overview Table 135. Kaneka Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Kaneka Cardiometabolic Disease Drug Product Portfolio Table 137. Kaneka Recent Development Table 138. Hengtai Chemical Company Information Table 139. Hengtai Chemical Business Overview Table 140. Hengtai Chemical Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Hengtai Chemical Cardiometabolic Disease Drug Product Portfolio Table 142. Hengtai Chemical Recent Development Table 143. Biosint Company Information Table 144. Biosint Business Overview Table 145. Biosint Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Biosint Cardiometabolic Disease Drug Product Portfolio Table 147. Biosint Recent Development Table 148. Abbott Company Information Table 149. Abbott Business Overview Table 150. Abbott Cardiometabolic Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Abbott Cardiometabolic Disease Drug Product Portfolio Table 152. Abbott Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Cardiometabolic Disease Drug Distributors List Table 156. Cardiometabolic Disease Drug Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Cardiometabolic Disease Drug Product Image Figure 2. Global Cardiometabolic Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cardiometabolic Disease Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Cardiometabolic Disease Drug Sales (2021-2032) & (K Units) Figure 5. Global Cardiometabolic Disease Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cardiometabolic Disease Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Coenzyme Q10 Image Figure 9. Cyclic Adenosine Monophosphate Image Figure 10. Trimetazidine Image Figure 11. L-carnitine Image Figure 12. Others Image Figure 13. Global Cardiometabolic Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Cardiometabolic Disease Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Cardiometabolic Disease Drug Sales Market Share by Type (2021-2032) Figure 16. Global Cardiometabolic Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Cardiometabolic Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Cardiometabolic Disease Drug Revenue Market Share by Type (2021-2032) Figure 19. Retail Pharmacy Image Figure 20. Online Sales Image Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Cardiometabolic Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Cardiometabolic Disease Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Cardiometabolic Disease Drug Sales Market Share by Application (2021-2032) Figure 27. Global Cardiometabolic Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Cardiometabolic Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Cardiometabolic Disease Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 44. China Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Cardiometabolic Disease Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Cardiometabolic Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Cardiometabolic Disease Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Cardiometabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Cardiometabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Cardiometabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Cardiometabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Cardiometabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Cardiometabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Cardiometabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Cardiometabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Cardiometabolic Disease Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Cardiometabolic Disease Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Coenzyme Q10
  • Cyclic Adenosine Monophosphate
  • Trimetazidine
  • L-carnitine
  • Others
Applications
  • Retail Pharmacy
  • Online Sales
  • Hospital
  • Clinic
  • Others
Companies covered
  • Qilu Pharmaceutical
  • Merck
  • Roche Holding AG
  • Chengda Pharmaceutical
  • ZMC
  • Taj Pharma
  • Sydler Group
  • Space Biology
  • Servier
  • Northeast Pharmaceutical
  • NHU
  • Lonza Group
  • Kingdomway
  • Kaneka
  • Hengtai Chemical
  • Biosint
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cardiometabolic Disease Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cardiometabolic Disease Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cardiometabolic Disease Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cardiometabolic Disease Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cardiometabolic Disease Drug Market Dynamics
  1. 2.1 Cardiometabolic Disease Drug Industry Trends
  2. 2.2 Cardiometabolic Disease Drug Industry Drivers
  3. 2.3 Cardiometabolic Disease Drug Industry Opportunities and Challenges
  4. 2.4 Cardiometabolic Disease Drug Industry Restraints
3 Cardiometabolic Disease Drug Market by Manufacturers
  1. 3.1 Global Cardiometabolic Disease Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cardiometabolic Disease Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cardiometabolic Disease Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cardiometabolic Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cardiometabolic Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cardiometabolic Disease Drug Manufacturers, Product Type & Application
  7. 3.7 Global Cardiometabolic Disease Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cardiometabolic Disease Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cardiometabolic Disease Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cardiometabolic Disease Drug Tier 1, Tier 2, and Tier 3
4 Cardiometabolic Disease Drug Market by Type
  1. 4.1 Cardiometabolic Disease Drug Type Introduction
  2. 4.1.1 Coenzyme Q10
  3. 4.1.2 Cyclic Adenosine Monophosphate
  4. 4.1.3 Trimetazidine
  5. 4.1.4 L-carnitine
  6. 4.1.5 Others
  7. 4.2 Global Cardiometabolic Disease Drug Sales by Type
  8. 4.2.1 Global Cardiometabolic Disease Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Cardiometabolic Disease Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Cardiometabolic Disease Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Cardiometabolic Disease Drug Revenue by Type
  12. 4.3.1 Global Cardiometabolic Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Cardiometabolic Disease Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Cardiometabolic Disease Drug Revenue Market Share by Type (2021-2032)
5 Cardiometabolic Disease Drug Market by Application
  1. 5.1 Cardiometabolic Disease Drug Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Sales
  4. 5.1.3 Hospital
  5. 5.1.4 Clinic
  6. 5.1.5 Others
  7. 5.2 Global Cardiometabolic Disease Drug Sales by Application
  8. 5.2.1 Global Cardiometabolic Disease Drug Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Cardiometabolic Disease Drug Sales by Application (2021-2032)
  10. 5.2.3 Global Cardiometabolic Disease Drug Sales Market Share by Application (2021-2032)
  11. 5.3 Global Cardiometabolic Disease Drug Revenue by Application
  12. 5.3.1 Global Cardiometabolic Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Cardiometabolic Disease Drug Revenue by Application (2021-2032)
  14. 5.3.3 Global Cardiometabolic Disease Drug Revenue Market Share by Application (2021-2032)
6 Global Cardiometabolic Disease Drug Sales by Region
  1. 6.1 Global Cardiometabolic Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cardiometabolic Disease Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Cardiometabolic Disease Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Cardiometabolic Disease Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cardiometabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cardiometabolic Disease Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cardiometabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cardiometabolic Disease Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cardiometabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cardiometabolic Disease Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cardiometabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cardiometabolic Disease Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cardiometabolic Disease Drug Revenue by Region
  1. 7.1 Global Cardiometabolic Disease Drug Revenue by Region
  2. 7.1.1 Global Cardiometabolic Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cardiometabolic Disease Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Cardiometabolic Disease Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Cardiometabolic Disease Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cardiometabolic Disease Drug Revenue (2021-2032)
  8. 7.2.2 North America Cardiometabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cardiometabolic Disease Drug Revenue (2021-2032)
  11. 7.3.2 Europe Cardiometabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cardiometabolic Disease Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cardiometabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cardiometabolic Disease Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cardiometabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Qilu Pharmaceutical
  2. 8.1.1 Qilu Pharmaceutical Company Information
  3. 8.1.2 Qilu Pharmaceutical Business Overview
  4. 8.1.3 Qilu Pharmaceutical Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Qilu Pharmaceutical Cardiometabolic Disease Drug Product Portfolio
  6. 8.1.5 Qilu Pharmaceutical Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Cardiometabolic Disease Drug Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Roche Holding AG
  14. 8.3.1 Roche Holding AG Company Information
  15. 8.3.2 Roche Holding AG Business Overview
  16. 8.3.3 Roche Holding AG Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Holding AG Cardiometabolic Disease Drug Product Portfolio
  18. 8.3.5 Roche Holding AG Recent Developments
  19. 8.4 Chengda Pharmaceutical
  20. 8.4.1 Chengda Pharmaceutical Company Information
  21. 8.4.2 Chengda Pharmaceutical Business Overview
  22. 8.4.3 Chengda Pharmaceutical Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chengda Pharmaceutical Cardiometabolic Disease Drug Product Portfolio
  24. 8.4.5 Chengda Pharmaceutical Recent Developments
  25. 8.5 ZMC
  26. 8.5.1 ZMC Company Information
  27. 8.5.2 ZMC Business Overview
  28. 8.5.3 ZMC Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ZMC Cardiometabolic Disease Drug Product Portfolio
  30. 8.5.5 ZMC Recent Developments
  31. 8.6 Taj Pharma
  32. 8.6.1 Taj Pharma Company Information
  33. 8.6.2 Taj Pharma Business Overview
  34. 8.6.3 Taj Pharma Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Taj Pharma Cardiometabolic Disease Drug Product Portfolio
  36. 8.6.5 Taj Pharma Recent Developments
  37. 8.7 Sydler Group
  38. 8.7.1 Sydler Group Company Information
  39. 8.7.2 Sydler Group Business Overview
  40. 8.7.3 Sydler Group Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sydler Group Cardiometabolic Disease Drug Product Portfolio
  42. 8.7.5 Sydler Group Recent Developments
  43. 8.8 Space Biology
  44. 8.8.1 Space Biology Company Information
  45. 8.8.2 Space Biology Business Overview
  46. 8.8.3 Space Biology Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Space Biology Cardiometabolic Disease Drug Product Portfolio
  48. 8.8.5 Space Biology Recent Developments
  49. 8.9 Servier
  50. 8.9.1 Servier Company Information
  51. 8.9.2 Servier Business Overview
  52. 8.9.3 Servier Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Servier Cardiometabolic Disease Drug Product Portfolio
  54. 8.9.5 Servier Recent Developments
  55. 8.10 Northeast Pharmaceutical
  56. 8.10.1 Northeast Pharmaceutical Company Information
  57. 8.10.2 Northeast Pharmaceutical Business Overview
  58. 8.10.3 Northeast Pharmaceutical Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Northeast Pharmaceutical Cardiometabolic Disease Drug Product Portfolio
  60. 8.10.5 Northeast Pharmaceutical Recent Developments
  61. 8.11 NHU
  62. 8.11.1 NHU Company Information
  63. 8.11.2 NHU Business Overview
  64. 8.11.3 NHU Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 NHU Cardiometabolic Disease Drug Product Portfolio
  66. 8.11.5 NHU Recent Developments
  67. 8.12 Lonza Group
  68. 8.12.1 Lonza Group Company Information
  69. 8.12.2 Lonza Group Business Overview
  70. 8.12.3 Lonza Group Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lonza Group Cardiometabolic Disease Drug Product Portfolio
  72. 8.12.5 Lonza Group Recent Developments
  73. 8.13 Kingdomway
  74. 8.13.1 Kingdomway Company Information
  75. 8.13.2 Kingdomway Business Overview
  76. 8.13.3 Kingdomway Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Kingdomway Cardiometabolic Disease Drug Product Portfolio
  78. 8.13.5 Kingdomway Recent Developments
  79. 8.14 Kaneka
  80. 8.14.1 Kaneka Company Information
  81. 8.14.2 Kaneka Business Overview
  82. 8.14.3 Kaneka Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Kaneka Cardiometabolic Disease Drug Product Portfolio
  84. 8.14.5 Kaneka Recent Developments
  85. 8.15 Hengtai Chemical
  86. 8.15.1 Hengtai Chemical Company Information
  87. 8.15.2 Hengtai Chemical Business Overview
  88. 8.15.3 Hengtai Chemical Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Hengtai Chemical Cardiometabolic Disease Drug Product Portfolio
  90. 8.15.5 Hengtai Chemical Recent Developments
  91. 8.16 Biosint
  92. 8.16.1 Biosint Company Information
  93. 8.16.2 Biosint Business Overview
  94. 8.16.3 Biosint Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Biosint Cardiometabolic Disease Drug Product Portfolio
  96. 8.16.5 Biosint Recent Developments
  97. 8.17 Abbott
  98. 8.17.1 Abbott Company Information
  99. 8.17.2 Abbott Business Overview
  100. 8.17.3 Abbott Cardiometabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Abbott Cardiometabolic Disease Drug Product Portfolio
  102. 8.17.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cardiometabolic Disease Drug Value Chain Analysis
  2. 9.1.1 Cardiometabolic Disease Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cardiometabolic Disease Drug Production Mode & Process
  6. 9.2 Cardiometabolic Disease Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cardiometabolic Disease Drug Distributors
  9. 9.2.3 Cardiometabolic Disease Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst